Evaluation of Phenobarbital and Benzodiazepine Use for Alcohol Withdrawal Treatment in the Medical Intensive Care Unit
Jessica Schuchardt, Mary W. Massaro, Benjamin T. Bevill, Micaela Seazzu, R. Eric Heidel, Madison Booker, Ashtyn Keller, Shauna D. WintersBackground:
There is a high prevalence of alcohol use disorder (AUD) leading to a significant risk of alcohol withdrawal syndrome (AWS) in critically ill patients. However, despite existing guidelines, there is limited evidence on the use of phenobarbital for AWS as part of a standardized protocol for medical intensive care unit (ICU) patients. This study aims to compare ICU length of stay for patients receiving phenobarbital and benzodiazepines versus benzodiazepines alone when treating AWS.
Methods:
This study was a single-center, retrospective, pre-post analysis that compared pre-pathway patients admitted between January 2017 and January 2020 who received benzodiazepines alone to post-pathway patients admitted between August 2022 and September 2024 who received phenobarbital in addition to benzodiazepines for AWS. Patients were included if they were hospitalized with an ICD-10 code for alcohol withdrawal, admitted to the ICU with medical critical care as the primary team, and, for the post-pathway group, must have received phenobarbital from the pathway. The primary outcome was ICU length of stay, while secondary outcomes included hospital length of stay, incidence and length of mechanical ventilation, cumulative benzodiazepines dose, incidence of delirium, and use of adjunctive medications for AWS.
Results:
A total of 132 patients were included in the analysis (n = 92 pre-pathway and n = 40 post-pathway). The median ICU length of stay for the pre-pathway group was 2.95 (interquartile range [IQR] 1.80-5.05) days compared to 2.60 (IQR 1.95-6.75) days for post-pathway group (
Conclusion and Relevance:
There was no significant difference found in the ICU length of stay between the pre-pathway group and the post-pathway group. However, the hospital length of stay for the post-pathway group was statistically shorter than that of the pre-pathway group. These findings suggest that phenobarbital seems to be safe and effective alternative for AWS, and benzodiazepine-sparing regimens should be considered.